TG Therapeutics
TGTXTGTX · Stock Price
Historical price data
Overview
TG Therapeutics has successfully transitioned into a commercial entity with the FDA approval of BRIUMVI for relapsing multiple sclerosis, establishing a core revenue stream. The company's strategy is anchored on its proprietary glycoengineering platform, which enhances antibody potency to target CD20 on B-cells. This validated approach underpins its pipeline expansion into broader autoimmune and oncology indications, aiming to capture significant market share in competitive therapeutic landscapes.
Technology Platform
Proprietary glycoengineering platform that creates afucosylated monoclonal antibodies to enhance FcγRIIIa binding and significantly amplify Antibody-Dependent Cellular Cytotoxicity (ADCC) for superior B-cell depletion.
Pipeline
43| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ublituximab | Multiple Sclerosis | Approved | |
| Ublituximab + Ocrelizumab | Multiple Sclerosis | Approved | |
| Ublituximab + Teriflunomide + Oral Placebo + IV Placebo | Relapsing Multiple Sclerosis (RMS) | Phase 3 | |
| Ublituximab + Teriflunomide + Oral Placebo + IV Placebo | Relapsing Multiple Sclerosis (RMS) | Phase 3 | |
| Ublituximab + Placebo | Relapsing Multiple Sclerosis | Phase 3 |
Funding History
4FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
BRIUMVI competes directly with other anti-CD20 therapies (ocrelizumab, ofatumumab) in a crowded MS market. In oncology, the competitive landscape is even more intense, featuring numerous approved targeted therapies, bispecific antibodies, and cell therapies, requiring TG's assets to demonstrate clear differentiation.